Company / Financials
InMed Pharmaceuticals Inc. Financials
FY2022-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableRevenue
$4.6M
FY2025 · +11.2% YoY
Net Income
-$7.7M
FY2025 · +3.4% YoY
Profit Margin
-166.9%
FY2025 · net income / revenue
ROE
-83.4%
FY2025 · return on equity
Total Assets
$15.6M
FY2025
Total Debt
-
FY2025
Equity
$9.2M
FY2025
ROA
-49.3%
FY2025 · return on assets
Statement paths
Financial highlights
Key Data Points
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Metric history
Revenue HistoryTotal revenue from operations$4.6M+11.2% YoYNet Income HistoryProfit after all expenses and taxes-$7.7M+3.4% YoYGross Profit HistoryRevenue minus cost of goods sold$1.1M-21.5% YoYCost of Revenue HistoryDirect costs of producing goods and services sold$3.5M+28.0% YoYOperating Income HistoryProfit from core business operations before interest and taxes-$18.6MSG&A Expense HistorySelling, general, and administrative expenses$5.8M-0.8% YoYR&D Expense HistoryResearch and development spending$3.2M-13.8% YoYInterest Expense HistoryCost of borrowing and debt obligations-$360.4KIncome Tax HistoryTotal income tax expense$7.1K-45.8% YoYEPS (Basic) HistoryBasic earnings per share-$20.14-519.7% YoY